{"id":"tak-788","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL3700823","moleculeType":"Small molecule","molecularWeight":"472.36"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"TAK-788 targets a specific class of EGFR mutations (exon 20 insertions) that confer resistance to standard EGFR tyrosine kinase inhibitors. By selectively inhibiting this mutant form of EGFR, the drug aims to block aberrant signaling that drives cancer cell proliferation in patients with these rare EGFR variants. This mechanism addresses an unmet need in non-small cell lung cancer patients who lack effective treatment options for exon 20 insertion mutations.","oneSentence":"TAK-788 is a selective inhibitor of epidermal growth factor receptor (EGFR) exon 20 insertion mutations.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:37:18.244Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer with EGFR exon 20 insertion mutations"}]},"trialDetails":[{"nctId":"NCT02716116","phase":"PHASE1, PHASE2","title":"A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2016-06-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":334},{"nctId":"NCT04051827","phase":"PHASE1","title":"Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2019-12-23","conditions":"Carcinoma, Non-Small-Cell Lung, Lung Neoplasms","enrollment":26},{"nctId":"NCT03807778","phase":"PHASE1","title":"A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2019-02-04","conditions":"Non-Small Cell Lung Cancer","enrollment":53},{"nctId":"NCT04129502","phase":"PHASE3","title":"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2020-01-10","conditions":"Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","enrollment":354},{"nctId":"NCT03811834","phase":"PHASE1","title":"A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2019-01-22","conditions":"Healthy Volunteers","enrollment":7},{"nctId":"NCT04056455","phase":"PHASE1","title":"A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2020-03-04","conditions":"Renal Impairment, Healthy Volunteers","enrollment":26},{"nctId":"NCT04056468","phase":"PHASE1","title":"A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2020-10-09","conditions":"Hepatic Impairment, Healthy Volunteers","enrollment":24},{"nctId":"NCT04441255","phase":"PHASE1","title":"A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-07-01","conditions":"Healthy Volunteers","enrollment":14},{"nctId":"NCT04576208","phase":"PHASE2","title":"A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2020-11-30","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":""},{"nctId":"NCT03928327","phase":"PHASE1","title":"A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2019-05-02","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT03482453","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2018-03-28","conditions":"Healthy Volunteers","enrollment":69}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mobocertinib","AP32788"],"phase":"phase_3","status":"active","brandName":"TAK-788","genericName":"TAK-788","companyName":"Millennium Pharmaceuticals, Inc.","companyId":"millennium-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TAK-788 is a selective inhibitor of epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Used for Non-small cell lung cancer with EGFR exon 20 insertion mutations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":7,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}